Small molecules combined with narrowband UVB therapy for psoriasis patients

Abstract

Psoriasis is a heterogeneous disease characterized by a wide range of clinical manifestations. Patients with psoriasis and psoriatic arthritis have an increased risk of developing comorbid conditions, therefore, when prescribing therapy, it is necessary to take into account aspects of polypharmacy and the risks of developing infections. Apremilast is effective for the treatment of patients with psoriasis and comorbid comorbidity. To increase the effectiveness of apremilast therapy (achieving PASI 90 and PASI 100), it is possible to use a combination with narrow-band medium-wave phototherapy. The combined method allows achieving clear or almost clear skin in the vast majority of patients and is highly safe, as evidenced by the absence of severe side effects. The method is safe when used in patients with impaired glucose tolerance, diabetes mellitus, increased body weight and the risk of infections.